"We made significant progress with our mavodelpar development programs and expanded both our leadership team and Board of Directors in 2022," said Gregory Flesher, President and CEO of Reneo Pharmaceuticals. "We recently achieved target enrollment of the STRIDE study and anticipate announcing topline results of this pivotal clinical trial in the fourth quarter of 2023. In addition, we anticipate dosing our first adult patient with PMM due to nDNA defects in the coming months, and expect to finalize our plans for the LC-FAOD Phase 2 program later this year. Finally, as we move closer towards the potential commercialization of mavodelpar, we have strengthened our financial, commercial, and operational expertise by making key changes to the leadership team and Board of Directors," concluded Flesher.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RPHM:
- Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies
- Reneo Pharmaceuticals achieves target enrollment in STRIDE study
- Reneo believes exposure to loss from SVB receivership is ‘immaterial’
- Reneo Pharmaceuticals to present REN001 data at SIMD meeting
